Vertex Pharmaceuticals (VRTX) Interest Expenses (2009 - 2025)

Vertex Pharmaceuticals' Interest Expenses history runs 10 years deep, the most recent figure standing at $3.3 million for Q4 2025.

• In Q4 2025, Interest Expenses rose 17.86% year-over-year to $3.3 million; the TTM figure through Mar 2026 stood at $10.3 million (down 55.6% YoY), while the FY2025 annual figure was $13.3 million, down 56.54% from the prior year.
• Interest Expenses was $3.3 million for Q4 2025 at Vertex Pharmaceuticals, roughly flat from $3.3 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $11.2 million in Q2 2023 to a low of $2.8 million in Q4 2024.
• Historically, Interest Expenses has averaged $7.0 million across 3 years, with a median of $7.5 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Interest Expenses tumbled 73.58% in 2024, then advanced 17.86% in 2025.
• A 3-year view of Interest Expenses shows it stood at $10.6 million in 2023, then sank by 73.58% to $2.8 million in 2024, then gained by 17.86% to $3.3 million in 2025.
• The last three Interest Expenses figures came in at $3.3 million (Q4 2025), $3.3 million (Q3 2025), and $3.7 million (Q2 2025), per Business Quant data.